Clinical trials: Pharmacodynamics
Relapsed/ Refractory Multiple Myeloma
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
- Trial name
- NCT03445663
- Testing
- AMG 424
- Where
- 8 sites in United States, Australia
- Volunteers
- 27 people
- Sponsor
- Xencor, Inc.
Actinic Keratosis (AK)
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic…
- Trial name
- NCT07318675
- Testing
- HW211026
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Cirrhosis
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics…
- Trial name
- NCT01114828
- Testing
- OPC-41061
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Asthma
A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma
This is a phase 1, safety study of CNTO 3157 in healthy subjects and subjects with asthma.
- Trial name
- NCT01195207
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Obesity, Overweight
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation…
- Trial name
- NCT07280936
- Testing
- SHR-2906 Injection
- Where
- China
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Healthy
Study Evaluating IMA-026 in Healthy Japanese Males
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending, single subcutaneous or intravenous doses of IMA-026 in healthy Japanese male subjects
- Trial name
- NCT00528099
- Testing
- IMA-026
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Participants
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of…
- Trial name
- NCT07918898
- Testing
- GZR101 80 Injection, GZR33 Injection, Insulin Aspart Injection
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT00935987
- Testing
- CYT387
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 166 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Cachexia
Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)
The aim of this early phase two-part study was to compare the bioavailability (BA) pharmacokinetics (PK) and pharmacodynamics (PD) of racemic pindolol with the benzoate salt of the S-enantiomer of pindolol (ACM-001.1) and provide…
- Trial name
- NCT06028321
- Testing
- Part 1 Group 1 Regime A (ACM-001.1), Part 1 Group 2 Regimen C (Pindolol), Part 2 Group D (Pindolol)
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Actimed Therapeutics Ltd
Overweight, Obesity
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
This is a 4-part study that includes a Part A, Part B, Part C, and Part D. Parts A and D will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese.
- Trial name
- NCT06606106
- Testing
- LY3537031
- Where
- 5 sites in United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Neutropenia
A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
This study was a phase Ib study of the safety and pharmacokinetics/pharmacodynamics of F-627 once per cycle as prophylaxis therapy to chemotherapy in women with breast cancer.
- Trial name
- NCT02522234
- Testing
- F-627 240 μg/kg, F-627 320 μg/kg
- Where
- China
- Volunteers
- 15 people
- Sponsor
- EVIVE Biotechnology
Healthy
Pharmacokinetics and Pharmacodynamics of the Interferon Beta-1a Produced by Laboratorio Quimico Farmaceutico Bergamo Compared to Interferon Beta-1a (Rebif - Merck Serono) in Healthy Subjects
The primary objective of this study is to compare the pharmacokinetic and pharmacodynamic effect of two commercial preparations of interferon beta-1a (IFN Test: Lab Bergamo and IFN Comparator: Rebif ® - Merck Serono Lab) after…
- Trial name
- NCT01074593
- Testing
- Interferon beta-1a
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Sleep Initiation and Maintenance Disorders
A Study of LY2624803 in Japanese Participants With Transient Insomnia
The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods.
- Trial name
- NCT01784614
- Testing
- LY2624803 - Solution, LY2624803 - Capsule
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metastatic Castration-resistant Prostate Cancer
A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
The primary purpose of this study is to evaluate the influence of HSD3B1 (1245C) germline variant and potential pharmacodynamic markers on abiraterone activity in participants with metastatic castration-resistant prostate cancer…
- Trial name
- EXPLORE (NCT04268628)
- Testing
- Serum and plasma samples analysis
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Healthy Subjects
Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.
This study will test the safety, tolerability and blood concentrations of single and multiple oral doses of PF-06751979 in health subjects and healthy elderly subjects.
- Trial name
- NCT02793232
- Testing
- PF-06751979 single dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C.
- Conditions
- Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome, Mitochondrial Myopathies
- Trial name
- NCT03888716
- Testing
- KL1333
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Abliva AB
MPS II, Hunter Syndrome (MPS II)
RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)
RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system.
- Trial name
- NCT07236606
- Testing
- RGX-121-3102
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- REGENXBIO Inc.
Diabetes Mellitus, Type 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
- Trial name
- NCT02038764
- Testing
- PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Osteoarthritis
A Study With GLPG1972 in Osteoarthritis Subjects
This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA)…
- Trial name
- NCT03311009
- Testing
- GLPG1972 cohort 1, GLPG1972 cohort 2, GLPG1972 cohort 3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lakefront Biotherapeutics NV
Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
- Trial name
- ALT-101 (NCT07586618)
- Testing
- 4A10
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Allterum Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.